Silent flagellin in chronic inflammatory and auto-immune disease
The SilentFlame project aims to investigate the role of silent flagellins from Lachnospiraceae in chronic inflammatory and autoimmune diseases to develop targeted therapeutic strategies.
Projectdetails
Introduction
The last century has seen a dramatic increase in the prevalence of chronic inflammatory and autoimmune illnesses, including diseases of poorly understood etiology such as Crohn’s disease (CD) and myalgic encephalomyelitis (ME). Recent reports for CD and ME of elevated levels of antibodies against flagellins made by Lachnospiraceae (Lachno), which are usually associated with health, suggest a common breakdown of immune tolerance.
Discovery of Silent Flagellins
My laboratory recently discovered a new class of flagellin that we termed “silent” because it binds the innate immune receptor TLR5 without inducing a response. Many Lachno species, which are highly abundant and prevalent in the human gut microbiome, encode silent flagellins. We have observed that silent flagellin is highly targeted by antibodies in CD and ME.
Hypothesis
We hypothesize that the usage of silent flagellins by Lachnos and their reciprocal interactions with host immunity sustain inflammation in the gut and may drive auto-immunity.
Research Objectives
In SilentFlame, we will explore the breadth of the antibody response against Lachno flagellins in a panel of chronic inflammatory and autoimmune conditions, as well as potential cross-reactivity with human proteins.
Investigative Approach
In parallel, we will investigate the enigmatic role of silent flagellin in bacterial colonization of the gut and host adaptive immune responses, both in homeostasis and inflammation. To do so, we will:
- Establish new genetic systems for two Lachno bacteria commonly associated with human health.
- Perform experiments in a germ-free transgenic mouse line expressing the human TLR5.
- Utilize human intestinal organoids to account for human-specific effects.
Expected Outcomes
This research will advance basic understanding of host-microbe reciprocal interactions in homeostasis and chronic inflammation. The knowledge gained will enable the development of targeted therapeutic strategies aimed at restoring balance and ameliorating the conditions that arise when this delicate equilibrium is disrupted.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.500.000 |
Totale projectbegroting | € 2.500.000 |
Tijdlijn
Startdatum | 1-1-2025 |
Einddatum | 31-12-2029 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EVpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Negative Regulation of Inflammatory Responses Revealed with Camelid NanobodiesThe project aims to develop new cell biology tools to uncover intricate signaling networks that downregulate inflammation, focusing on the roles of NLRC3 and NLRX1 in controlling pro-inflammatory responses. | ERC Consolid... | € 1.997.828 | 2024 | Details |
Deciphering host-gut microbiota spatio-functional plasticity in inflammationThis project aims to investigate the spatiofunctional plasticity of gut bacteria in Crohn's disease, exploring host-microbe interactions and their impact on inflammation using advanced microbiological and immunological methods. | ERC Starting... | € 1.997.500 | 2023 | Details |
T cell regulation by fed state bacterial metabolitesThis project aims to identify immunoregulatory bacterial molecules produced in response to food intake, enhancing understanding of gut microbiome tolerance mechanisms and their impact on intestinal health. | ERC Starting... | € 1.499.548 | 2024 | Details |
Deciphering and Exploiting the chemical features of Silent Lipopolysaccharides: a gift from gut microbiotaDEBUGGING-LPS aims to decipher the chemical language of lipopolysaccharides in gut microbiota to differentiate between beneficial and harmful interactions, paving the way for new immune disorder therapies. | ERC Starting... | € 1.954.308 | 2022 | Details |
Microbiota-T cell interactions - antigen-specificity and regulation in health and diseaseThis project aims to identify and characterize microbe-specific T cells to understand their role in chronic inflammatory diseases and aging, paving the way for targeted therapies. | ERC Starting... | € 1.500.000 | 2022 | Details |
Negative Regulation of Inflammatory Responses Revealed with Camelid Nanobodies
The project aims to develop new cell biology tools to uncover intricate signaling networks that downregulate inflammation, focusing on the roles of NLRC3 and NLRX1 in controlling pro-inflammatory responses.
Deciphering host-gut microbiota spatio-functional plasticity in inflammation
This project aims to investigate the spatiofunctional plasticity of gut bacteria in Crohn's disease, exploring host-microbe interactions and their impact on inflammation using advanced microbiological and immunological methods.
T cell regulation by fed state bacterial metabolites
This project aims to identify immunoregulatory bacterial molecules produced in response to food intake, enhancing understanding of gut microbiome tolerance mechanisms and their impact on intestinal health.
Deciphering and Exploiting the chemical features of Silent Lipopolysaccharides: a gift from gut microbiota
DEBUGGING-LPS aims to decipher the chemical language of lipopolysaccharides in gut microbiota to differentiate between beneficial and harmful interactions, paving the way for new immune disorder therapies.
Microbiota-T cell interactions - antigen-specificity and regulation in health and disease
This project aims to identify and characterize microbe-specific T cells to understand their role in chronic inflammatory diseases and aging, paving the way for targeted therapies.